−7.65USD
−42.19 MUSD
2.24 MUSD
7.48 M
About SAB Biotherapeutics, Inc.
Sector
Industry
CEO
Samuel J. Reich
Website
Headquarters
Sioux Falls
Employees (FY)
57
Founded
2014
ISIN
US78397T2024
FIGI
BBG00YHY0G24
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Sioux Falls, SD.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SABS is 4.46 USD — it has decreased by 3.04% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange SAB Biotherapeutics, Inc. stocks are traded under the ticker SABS.
SAB Biotherapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
SABS stock is 8.44% volatile and has beta coefficient of −0.55. Check out the list of the most volatile stocks — is SAB Biotherapeutics, Inc. there?
One year price forecast for SAB Biotherapeutics, Inc. has a max estimate of 25.00 USD and a min estimate of 6.00 USD.
SABS earnings for the last quarter are −1.00 USD per share, whereas the estimation was −1.17 USD resulting in a 14.29% surprise. The estimated earnings for the next quarter are −0.62 USD per share. See more details about SAB Biotherapeutics, Inc. earnings.
SAB Biotherapeutics, Inc. revenue for the last quarter amounts to 100.00 K USD despite the estimated figure of 400.00 K USD. In the next quarter revenue is expected to reach 11.97 K USD.
Yes, you can track SAB Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
SABS stock has fallen by 0.89% compared to the previous week, the month change is a 18.17% fall, over the last year SAB Biotherapeutics, Inc. has showed a 51.95% decrease.
SABS net income for the last quarter is −22.86 M USD, while the quarter before that showed −5.10 M USD of net income which accounts for −347.97% change. Track more SAB Biotherapeutics, Inc. financial stats to get the full picture.
Today SAB Biotherapeutics, Inc. has the market capitalization of 41.15 M, it has decreased by 0.89% over the last week.
No, SABS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, SABS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SAB Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 57.00 employees. See our rating of the largest employees — is SAB Biotherapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SAB Biotherapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SAB Biotherapeutics, Inc. stock shows the sell signal. See more of SAB Biotherapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SAB Biotherapeutics, Inc. future price: according to them, SABS price has a max estimate of 25.00 USD and a min estimate of 6.00 USD. Read a more detailed SAB Biotherapeutics, Inc. forecast: see what analysts think of SAB Biotherapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SAB Biotherapeutics, Inc. EBITDA is −34.33 M USD, and current EBITDA margin is −1.53 K%. See more stats in SAB Biotherapeutics, Inc. financial statements.